1. Medtech Insight
  2. >>Device Area

NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020

 
• By Marion Webb

At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.

Sep 16, 2019 Fremont / CA / USA - Boston Scientific office buildings in Silicon Valley; Boston Scientific Corporation is a manufacturer of medical devices used in interventional medical specialties

At the North American Neuromodulation Society (NANS) meeting, Boston Scientific Corp. highlighted encouraging three-month results from a randomized trial of its Spectra Wavewriter spinal cord stimulator and other plans for its neuromodulation business that include a partnership with IBM Research using machine learning tools to gain an objective understanding of patients' pain.

Results of the 89-patient randomized Combining Mechanisms for Better Outcomes (COMBO) study, sponsored by Boston Scientific, showed more patients responded to a novel combination spinal-cord stimulation (SCS) therapy delivered...

More from Neurology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.